LS Investment Advisors LLC continued to hold its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 731 shares of the specialty pharmaceutical company’s stock at the end of the second quarter. LS Investment Advisors LLC’s holdings in Jazz Pharmaceuticals PLC were worth $114,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in JAZZ. Envestnet Asset Management Inc. raised its stake in shares of Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock valued at $141,000 after buying an additional 295 shares during the period. World Asset Management Inc bought a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter valued at about $205,000. Private Advisor Group LLC bought a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter valued at about $215,000. Mn Services Vermogensbeheer B.V. raised its stake in shares of Jazz Pharmaceuticals PLC by 2.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 1,601 shares of the specialty pharmaceutical company’s stock valued at $217,000 after buying an additional 44 shares during the period. Finally, Logan Capital Management Inc. bought a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter valued at about $223,000. Institutional investors and hedge funds own 86.43% of the company’s stock.

Shares of Jazz Pharmaceuticals PLC (JAZZ) traded down 0.66% during trading on Friday, reaching $142.71. 476,916 shares of the company’s stock were exchanged. Jazz Pharmaceuticals PLC has a 52 week low of $95.80 and a 52 week high of $163.75. The stock has a 50 day moving average price of $154.90 and a 200-day moving average price of $146.69. The stock has a market capitalization of $8.57 billion, a price-to-earnings ratio of 21.98 and a beta of 1.10.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The firm had revenue of $394.39 million for the quarter, compared to analyst estimates of $410.83 million. During the same period in the prior year, the business earned $2.67 earnings per share. Jazz Pharmaceuticals PLC’s revenue for the quarter was up 3.5% on a year-over-year basis. Analysts predict that Jazz Pharmaceuticals PLC will post $10.87 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/jazz-pharmaceuticals-plc-jazz-position-maintained-by-ls-investment-advisors-llc/1479765.html.

Several analysts have recently issued reports on JAZZ shares. Leerink Swann set a $179.00 target price on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Thursday, April 27th. Cantor Fitzgerald reiterated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, April 27th. Zacks Investment Research upgraded shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $174.00 target price on the stock in a research report on Monday, May 15th. Vetr upgraded shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 target price on the stock in a research report on Tuesday, June 6th. Finally, Royal Bank Of Canada set a $210.00 target price on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Tuesday, June 27th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $182.72.

In other Jazz Pharmaceuticals PLC news, EVP Suzanne Sawochka Hooper sold 420 shares of the firm’s stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $160.00, for a total transaction of $67,200.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $152.98, for a total transaction of $30,596.00. Following the sale, the executive vice president now directly owns 22,623 shares in the company, valued at $3,460,866.54. The disclosure for this sale can be found here. Insiders have sold a total of 10,600 shares of company stock worth $1,641,720 over the last ninety days. 4.30% of the stock is owned by corporate insiders.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.